BackCumberland Pharmaceuticals Overview

Cumberland Pharmaceuticals Total Revenue

Track Cumberland Pharmaceuticals's total revenue ($31M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$166458.00
98.46% YoY

As of Jun 2026

Annual Revenue (TTM)

$31.27M
25.68% YoY

Trailing 12 months ending Jun 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Cumberland Pharmaceuticals (CPIX) FAQ

As of the most recent data (June 2026), CPIX shows a total revenue of $31M. That compares with $42M in the prior-year period — down 25.7% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CPIX's total revenue is now $31M (was $42M) — a 25.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cumberland Pharmaceuticals is outperforming or lagging.

The Healthcare sector average total revenue is about $110B. Cumberland Pharmaceuticals is at $31M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CPIX stacks up against individual peers as well.

Tracking CPIX's total revenue over time shows whether Cumberland Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $31M That compares with $42M in the prior-year period — down 25.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Cumberland Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $31M) with ownership activity and broader fundamentals.